P53-specific T cell responses in patients with malignant and benign ovarian tumors: implications for p53 based immunotherapy.
Lambeck A, Leffers N, Hoogeboom BN, Sluiter W, Hamming I, Klip H, ten Hoor K, Esajas M, van Oven M, Drijfhout JW, Platteel I, Offringa R, Hollema H, Melief K, van der Burg S, van der Zee A, Daemen T, Nijman H.
Lambeck A, et al. Among authors: daemen t.
Int J Cancer. 2007 Aug 1;121(3):606-14. doi: 10.1002/ijc.22710.
Int J Cancer. 2007.
PMID: 17415711